ABC294640 Opaganib

具體成交價(jià)以合同協(xié)議為準(zhǔn)

公司名稱(chēng) MedChemExpress LLC
品牌 MedChemExpress (MCE)
型號(hào) ABC294640
產(chǎn)地
廠商性質(zhì) 生產(chǎn)廠家
更新時(shí)間 2019/7/11 17:41:10
訪(fǎng)問(wèn)次數(shù) 664

產(chǎn)品標(biāo)簽

ABC294640 opaganib

在線(xiàn)交流發(fā)送詢(xún)價(jià) 查看電話(huà) 同類(lèi)產(chǎn)品

聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!

索取相關(guān)資料

公司介紹 主營(yíng)產(chǎn)品

MedChemExpress (MCE) 專(zhuān)注于為科學(xué)家提供高品質(zhì)的生物活性小分子化合物，化合物庫(kù)及各類(lèi)試劑盒，總部位于美國(guó)新澤西。
•   MedChemExpress (MCE) 產(chǎn)品作用于 20 多個(gè)熱門(mén)信號(hào)通路及研究領(lǐng)域的300多個(gè)細(xì)分靶點(diǎn)，擁有 10000 特異性抑制劑、激動(dòng)劑，以及 50 活性化合物篩選庫(kù)；
•   我們堅(jiān)持對(duì)所有產(chǎn)品進(jìn)行嚴(yán)格質(zhì)檢，確保產(chǎn)品的高品質(zhì)和高純度；
•   MedChemExpress (MCE) 產(chǎn)品已被數(shù)萬(wàn)名科學(xué)家信賴(lài)，并被大量top文獻(xiàn)和*引用；
•   我們擁有專(zhuān)業(yè)的技術(shù)團(tuán)隊(duì)追蹤前沿科研進(jìn)展，不斷豐富各個(gè)靶點(diǎn)的特異性產(chǎn)品，堅(jiān)持做 “您身邊的抑制劑大師”；
•   MedChemExpress (MCE) 與眾多藥企和科研機(jī)構(gòu)保持深度合作；
•   大量產(chǎn)品有中國(guó)庫(kù)存，工作日 16:00 前訂單確保當(dāng)日發(fā)貨，次日送達(dá)。
MCE 中國(guó)站：www.MedChemExpress.cn

Hotline: 400-820-3792
Tel: 021-58955995
Email: sales@MedChemExpress.cn
Tech Support: 021-58950656

MedChemExpress - Inhibitors Agonists

MedChemExpress - Screening Libraries

MedChemExpress - Top Publications Citing Use of MCE

展開(kāi)

抑制劑，調(diào)節(jié)劑，API，天然產(chǎn)物，各種類(lèi)型化合物庫(kù)

詳細(xì)信息 在線(xiàn)詢(xún)價(jià)

供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL；5 mg；10 mg
貨號(hào)	HY-16015	應(yīng)用領(lǐng)域	生物產(chǎn)業(yè)

Opaganib

產(chǎn)品活性：Opaganib (ABC294640) 是一種選擇性的競(jìng)爭(zhēng)性的鞘氨醇激酶 2 (SK2) 抑制劑，K_i 為 9.8 μM。

研究領(lǐng)域：Immunology/Inflammation

作用靶點(diǎn)：SPHK

In Vitro: Using recombinant human SK1 and SK2, Opaganib demonstrates dose-dependent inhibition of SK2 with an IC₅₀ of approximately 60 μM without affecting the activity of SK1 at concentrations up to at least 100 μM. In contrast, N,N-dimethylsphingosine (DMS) inhibits both SK1 and SK2 with IC₅₀ values of approximately 60 and 20 μM, respectively. Kinetic analyses of varying concentrations of Opaganib (ABC294640) in the presence of 2.5 to 25 μM sphingosine indicated a K_i of 9.8±1.4 μM for the inhibition of SK2. Opaganib (ABC294640) decreases [³H]S1P formation in a dose-dependent fashion with an IC₅₀ value of 26 μM. IC₅₀ values for Opaganib (ABC294640) are approximately 50 and 60 μM for A-498 and Bxpc-3 cells, respectively; whereas the IC₅₀ values for Opaganib (ABC294640) are approximately 20 and 40 μM for these cells.

In Vivo: Opaganib induces a transient minor decrease in the hematocrit of rats. Hematology studies indicate decreases in red blood cell number and hematocrit of approximately 20% in animals given either 100 or 250 mg/kg/day; and a slight increase in neutrophils and decrease in basophils in the treated rats. Mice are gavaged with Opaganib (50 mg/kg), a selective inhibitor of sphingosine kinase-2 (SK2), 1 h before surgery and subjected to 1 h-warm ischemia to ~70% of the liver followed by reperfusion. Opaganib-treatment largely prevented the increase of sphingosine-1-phosphate (S1P) after ischemia-reperfusion (IR) in vivo.